Amgen Reports final analysis Data for Reslizumab in Endometrial cancer

Amgen today announced final analysis results for Reslizumab in patients with Endometrial cancer. The study demonstrated that Reslizumab reduces biomarker levels substantially compared to standard of care or placebo. These results provide important insights into the treatment of Endometrial cancer and support the continued development of Reslizumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Reslizumab was consistent with previous observations, with no new safety signals identified.